Post-traumatic stress disorders - Pipeline Insight, 2021
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Post-traumatic stress disorders - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Post-traumatic stress disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Post-traumatic stress disorders: Overview
Post-traumatic stress disorder (PTSD) is a psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape or who have been threatened with death, sexual violence or serious injury. PTSD affects approximately 3.5 percent of U.S. adults every year, and an estimated one in 11 people will be diagnosed with PTSD in their lifetime. Women are twice as likely as men to have PTSD.
Symptoms of PTSD fall into four categories. Specific symptoms can vary in severity. Intrusion, Avoidance, Alterations in cognition and mood, Alterations in arousal and reactivity. A diagnosis of PTSD requires exposure to an upsetting traumatic event. However, the exposure could be indirect rather than first hand. Treatment usually involves psychotherapy and counseling, medication, or a combination. Options for psychotherapy will be specially tailored for managing trauma. They include: Cognitive processing therapy (CPT), Exposure therapy. Some medications can be used to treat the symptoms of PTSD. Selective serotonin reuptake inhibitors (SSRIs), such as paroxetine, are commonly used. SSRIs also help treat depression, anxiety and sleep problems, symptoms that are often linked to PTSD.
Report Highlights
This segment of the Post-traumatic stress disorders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Post-traumatic stress disorders Emerging Drugs
It is currently in Phase III stage of development for Post-traumatic stress disorders and is being developed by Tonix Pharmaceuticals.
It is currently in Phase II stage of development for Post-traumatic stress disorders and is being developed by Aptinyx
Further product details are provided in the report..
Post-traumatic stress disorders: Therapeutic Assessment
This segment of the report provides insights about the different Post-traumatic stress disorders drugs segregated based on following parameters that define the scope of the report, such as:
Post-traumatic stress disorders: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Post-traumatic stress disorders therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-traumatic stress disorders drugs.
Post-traumatic stress disorders Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Post-traumatic stress disorders - Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Post-traumatic stress disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Post-traumatic stress disorders: Overview
Post-traumatic stress disorder (PTSD) is a psychiatric disorder that may occur in people who have experienced or witnessed a traumatic event such as a natural disaster, a serious accident, a terrorist act, war/combat, or rape or who have been threatened with death, sexual violence or serious injury. PTSD affects approximately 3.5 percent of U.S. adults every year, and an estimated one in 11 people will be diagnosed with PTSD in their lifetime. Women are twice as likely as men to have PTSD.
Symptoms of PTSD fall into four categories. Specific symptoms can vary in severity. Intrusion, Avoidance, Alterations in cognition and mood, Alterations in arousal and reactivity. A diagnosis of PTSD requires exposure to an upsetting traumatic event. However, the exposure could be indirect rather than first hand. Treatment usually involves psychotherapy and counseling, medication, or a combination. Options for psychotherapy will be specially tailored for managing trauma. They include: Cognitive processing therapy (CPT), Exposure therapy. Some medications can be used to treat the symptoms of PTSD. Selective serotonin reuptake inhibitors (SSRIs), such as paroxetine, are commonly used. SSRIs also help treat depression, anxiety and sleep problems, symptoms that are often linked to PTSD.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Post-traumatic stress disorders R&D. The therapies under development are focused on novel approaches for Post-traumatic stress disorders.
This segment of the Post-traumatic stress disorders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Post-traumatic stress disorders Emerging Drugs
- TNX-102 SL: Tonix Pharmaceuticals
It is currently in Phase III stage of development for Post-traumatic stress disorders and is being developed by Tonix Pharmaceuticals.
- NYX-783: Aptinyx
It is currently in Phase II stage of development for Post-traumatic stress disorders and is being developed by Aptinyx
Further product details are provided in the report..
Post-traumatic stress disorders: Therapeutic Assessment
This segment of the report provides insights about the different Post-traumatic stress disorders drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Post-traumatic stress disorders
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Post-traumatic stress disorders: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Post-traumatic stress disorders therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Post-traumatic stress disorders drugs.
Post-traumatic stress disorders Report Insights
- Post-traumatic stress disorders Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Post-traumatic stress disorders drugs?
- How many Post-traumatic stress disorders drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Post-traumatic stress disorders?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Post-traumatic stress disorders therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Post-traumatic stress disorders and their status?
- What are the key designations that have been granted to the emerging drugs?
- Tonix Pharmaceuticals
- Nobilis Therapeutics
- Bionorica
- H. Lundbeck A/S
- Bionomics
- Jazz Pharmaceuticals
- Chronos Therapeutic
- PSY Therapeutics
- VistaGen Therapeutics
- Aptiny
- Alzamend
- TNX-102 SL
- TNX-601
- TNX-1600
- NBTX-001
- BX-1
- Lu AG06466
- BNC210
- JZP-150
- PSY-05
- PH94B
- NYX-783
- AL001
Introduction
Executive Summary
Post-traumatic stress disorders: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Post-traumatic stress disorders– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Post-traumatic stress disorders companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Post-traumatic stress disorders Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TNX-102 SL: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
NYX-783: Aptinyx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Lu AG06466: H. Lundbeck A/S
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
TNX-1600: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Post-traumatic stress disorders Key Companies
Post-traumatic stress disorders Key Products
Post-traumatic stress disorders- Unmet Needs
Post-traumatic stress disorders- Market Drivers and Barriers
Post-traumatic stress disorders- Future Perspectives and Conclusion
Post-traumatic stress disorders Analyst Views
Post-traumatic stress disorders Key Companies
Appendix
Executive Summary
Post-traumatic stress disorders: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Post-traumatic stress disorders– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Post-traumatic stress disorders companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Post-traumatic stress disorders Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
TNX-102 SL: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
NYX-783: Aptinyx
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
Lu AG06466: H. Lundbeck A/S
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
TNX-1600: Tonix Pharmaceuticals
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Post-traumatic stress disorders Key Companies
Post-traumatic stress disorders Key Products
Post-traumatic stress disorders- Unmet Needs
Post-traumatic stress disorders- Market Drivers and Barriers
Post-traumatic stress disorders- Future Perspectives and Conclusion
Post-traumatic stress disorders Analyst Views
Post-traumatic stress disorders Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Post-traumatic stress disorders
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Post-traumatic stress disorders
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Post-traumatic stress disorders
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Post-traumatic stress disorders
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
